TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03757754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 2.5 mg/m2
Description: HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 3 mg/m2
Description: HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 3.5 mg/m2
Description: HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 4 mg/m2
Description: HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 5 mg/m2
Description: HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 6 mg/m2
Description: HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Study: NCT00513396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Study: NCT04166760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: speWHE
Description: 25 gram of a specific whey fraction (confidential)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WHE
Description: 25 gram protein of a regular whey compound
Study: NCT00969072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.05mg
Description: GI198745 (drug) - benign prostatic hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.5mg
Description: GI198745 (drug) - benign prostatic hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 2.5mg
Description: GI198745 (drug) - benign prostatic hyperplasia
Study: NCT01803867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rHIgM22
Description: Administered via IV infusion
Study: NCT03481621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: PT, pain medications, nerve block, etc
Study: NCT04445376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercises
Description: Aerobic Training and Breathing Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercises
Description: Aerobic Training and Breathing Exercises.
Study: NCT02851823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal curettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er-YAG+Nd-YAG lasers
Study: NCT02530736

Intervention type: OTHER
Intervention: 4 metre gait speed
Description: Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
Study: NCT02584920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT03765827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamine E Acetate
Description: Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No application of vitamin E acetate
Description: Vitamin E acetate ointment will not be applied in this group
Study: NCT01454570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: powered exoskeleton
Study: NCT00772707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)
Description: OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses
Description: Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
Study: NCT01275833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-defibrillator
Description: Device programming that modifies AV timing
Study: NCT03451149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency wire (Powerwire)
Description: Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
Study: NCT02382679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Vitamin Mixture
Description: Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
Study: NCT01014429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-1286937
Description: Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
Study: NCT02046408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Tablet
Study: NCT02041533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study: NCT03562728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRP and NMES(neuromuscular electric stimulation)
Description: nutrition supplementation includes addition of essential amino acids 3 times a day to feeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRP and NMES(neuromuscular electric stimulation)
Description: nutrition supplementation includes addition of essential amino acids 3 times a day to feeding

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients in the control group are going to receive standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients in the control group are going to receive standard of care
Study: NCT04789005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Study: NCT01475227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Solvazinc tablet, day 2 to day 15
Description: Zinc sulphate 125mg, day 2 to day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Solvazinc tablet, day 15 to day 28
Description: Zinc sulphate 125mg, day 15 to day 28
Study: NCT02005679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: application of the mini-mental state test
Study: NCT02065479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of platelet reactivity between prasugrel and ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between prasugrel and ticagrelor
Study: NCT04018833

Intervention type: DRUG
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

Intervention type: DRUG
Intervention: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]
Study: NCT00529854

Intervention type: OTHER
Intervention: SIC-IR Billing Module
Description: Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
Study: NCT00803868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: up to 1mg po bid for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching study drug up to 1mg po bid
Study: NCT05398432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes.
Study: NCT01561820

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5-month aerobic exercise intervention
Description: The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 5-month aerobic exercise intervention
Description: The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
Study: NCT03491995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Description: Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
Study: NCT02356198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal hydromorphone
Description: Intrathecal opioid administration
Study: NCT04008953

Intervention type: DEVICE
Intervention: ultrasonography
Description: Intravascular volume assessment using ultrasonography, CVP and echocardiography
Study: NCT01366352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNTX tablet (Formulation 1)
Study: NCT01562327

Intervention type: DRUG
Intervention: Tocilizumab
Description: Participants received tocilizumab according to individualized physician-prescribed regimens.
Study: NCT04083521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111®
Description: Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
Study: NCT02312375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
Study: NCT01366352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNTX tablet (Formulation 2)
Study: NCT02042092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT01238965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT02198183

Intervention type: DEVICE
Intervention: Casmed Fore-Sight Elite

Intervention type: DEVICE
Intervention: Non-invasive Cardiac Output Monitor (NICOM)
Study: NCT03243981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton SkinTyte (800-1800 nm) with Broadband Light Technology
Description: This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
Study: NCT01483378

Intervention type: OTHER
Group type: OTHER
Intervention: Choosing to receive the vaccine
Study: NCT02147964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1% Gel
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1% Gel
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1% Gel
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]
Study: NCT00281359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With heat
Description: heat pad followed by dynamic splinting

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No heat
Description: No heat added to tissue prior to dynamic splinting
Study: NCT01831570

Intervention type: OTHER
Group type: OTHER
Intervention: GENETIC and radiographs
Description: GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
Study: NCT01238965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study: NCT01416428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oprozomib
Description: Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oprozomib
Description: Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
Study: NCT02042092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Study: NCT00787475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health worker
Description: Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
Study: NCT01020578

Intervention type: OTHER
Intervention: Plasma kinetic study
Description: This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.

Intervention type: OTHER
Intervention: Plasma kinetic study
Description: This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
Study: NCT01631916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
Study: NCT00651599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Study: NCT01697826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinSupV3 -soft gelatin capsule
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinSupV3ER- Extended release tablet
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
Study: NCT02404298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Study: NCT03178591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study: NCT02796495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Operation of hand prosthesis with direct nerve stimulation
Description: Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention.
Study: NCT02040038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE
Description: 3-D Virtual Environment for DSMT/S
Study: NCT02147964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone 1% Gel
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]
Study: NCT02040038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: 2-D Website participation for DSMT/S